NoorSadaNoorSada
BREAKINGHealthDeveloping✓ 1 source

Nine deaths in Alicante tied to Nolotil ingredient, seven of them British

A study presented to Spain's hospital pharmacy society links metamizol to agranulocytosis in five Alicante health departments, with UK-born patients at 78.8 times the relative risk.

Speed:

PD
Pierre Dubois
· 2 min read
Interior of a pharmacy · Photo: ManzoorRph / Wikimedia Commons (CC BY-SA 4.0)

Nine people died of agranulocytosis linked to metamizol in Alicante province in 2016 and 2017, seven of them British, a study presented at the congress of the Sociedad Española de Farmacia Hospitalaria (SEFH) has found. The molecule is the active ingredient of Nolotil, Spain's best-selling branded medicine, used for pain and high fever.

Staff at the Hospital Francesc de Borja de Gandía based the work on a 2019 internal report by the Generalitat Valenciana that has never been published. It covers five health departments — Denia, Villajoyosa, Torrevieja, San Juan and Orihuela — with 916,000 inhabitants, of whom 62,000 were born in the United Kingdom and 28,000 in other northern European countries.

Of 41 patients hospitalised with agranulocytosis from metamizol, 26 were British, 11 Spanish, and one each Danish, Dutch, Swedish and Moroccan. Agranulocytosis is a drastic fall in granulocytes, a type of white blood cell, and can be fatal.

The study puts the rate among Spanish patients at 0.33 cases per 100,000 defined daily doses, against 39.8 among people of UK origin — a relative risk 120.7 times higher. Per 1,000 patients treated it records 0.084 cases among Spaniards, about one in 12,000, and 6.62 among Britons, one in 151, a relative risk 78.8 times higher.

Metamizol was first marketed in Germany in 1922 and remains widely used there, in Austria, Italy, Portugal, Russia and Turkey. Belgium and the Netherlands keep it approved but tightly restricted. France, Sweden, Denmark, the United Kingdom, Ireland, the United States and about thirty other countries have withdrawn it over its link to agranulocytosis.

The Agencia Española del Medicamento y Productos Sanitarios (AEMPS) says available information neither confirms nor rules out a higher risk in specific ethnic or genetic populations, and that the benefit-risk balance remains positive. In 2018 it recommended not using the drug beyond a week and advised against it in the floating population. José Luis Marco Garbayo, the study's author, said the note refers to tourists while the risk lies with residents of those countries.

The AEMPS rejects the report's conclusions, writing that it "is not analytical, but descriptive" and does not allow incidences or relative risks to be calculated. Between 2023 and 2024 the European Medicines Agency (EMA) re-evaluated the drug after Finland decided to withdraw it, concluding that benefits still outweighed risks while pushing changes to patient leaflets to make complications easier to detect.

Sources — how we know this

#Health○ ...